The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Trevor Silverstone - One of the best experts on this subject based on the ideXlab platform.
-
Growth hormone and prolactin response to apomorphine in bipolar and Unipolar Depression.
Journal of affective disorders, 2003Co-Authors: Heather Mcpherson, Anne Walsh, Trevor SilverstoneAbstract:It has been suggested that patients with bipolar disorder may have an increased sensitivity to dopaminergic (DA) compounds. This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar Depression, Unipolar Depression and control subjects. Fourteen patients in an episode of bipolar Depression (BP), 15 in an episode of Unipolar Depression (UP) and 19 age- and gender-matched control subjects (C) participated. The growth hormone (GH) and prolactin (PRL) responses to subcutaneous administration of 0.005 or 0.008 mg/kg APO were measured over 2 h. The rise in GH was greater with the higher APO dose. Both the GH rise and the PRL fall following APO were similar in BP, UP and C. Neither the GH or PRL responses in BP and UP were affected by successful treatment of the depressive episode. Our findings do not indicate an altered sensitivity of DA neurones in the hypothalamic-pituitary system in either bipolar or Unipolar Depression.
-
Growth hormone and prolactin response to apomorphine in bipolar and Unipolar Depression.
Journal of Affective Disorders, 2002Co-Authors: Heather Mcpherson, Anne E.s. Walsh, Trevor SilverstoneAbstract:Abstract Background: It has been suggested that patients with bipolar disorder may have an increased sensitivity to dopaminergic (DA) compounds. This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar Depression, Unipolar Depression and control subjects. Methods: Fourteen patients in an episode of bipolar Depression (BP), 15 in an episode of Unipolar Depression (UP) and 19 age- and gender-matched control subjects (C) participated. The growth hormone (GH) and prolactin (PRL) responses to subcutaneous administration of 0.005 or 0.008 mg/kg APO were measured over 2 h. Results: The rise in GH was greater with the higher APO dose. Both the GH rise and the PRL fall following APO were similar in BP, UP and C. Neither the GH or PRL responses in BP and UP were affected by successful treatment of the depressive episode. Conclusion: Our findings do not indicate an altered sensitivity of DA neurones in the hypothalamic–pituitary system in either bipolar or Unipolar Depression.
Heather Mcpherson - One of the best experts on this subject based on the ideXlab platform.
-
Growth hormone and prolactin response to apomorphine in bipolar and Unipolar Depression.
Journal of affective disorders, 2003Co-Authors: Heather Mcpherson, Anne Walsh, Trevor SilverstoneAbstract:It has been suggested that patients with bipolar disorder may have an increased sensitivity to dopaminergic (DA) compounds. This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar Depression, Unipolar Depression and control subjects. Fourteen patients in an episode of bipolar Depression (BP), 15 in an episode of Unipolar Depression (UP) and 19 age- and gender-matched control subjects (C) participated. The growth hormone (GH) and prolactin (PRL) responses to subcutaneous administration of 0.005 or 0.008 mg/kg APO were measured over 2 h. The rise in GH was greater with the higher APO dose. Both the GH rise and the PRL fall following APO were similar in BP, UP and C. Neither the GH or PRL responses in BP and UP were affected by successful treatment of the depressive episode. Our findings do not indicate an altered sensitivity of DA neurones in the hypothalamic-pituitary system in either bipolar or Unipolar Depression.
-
Growth hormone and prolactin response to apomorphine in bipolar and Unipolar Depression.
Journal of Affective Disorders, 2002Co-Authors: Heather Mcpherson, Anne E.s. Walsh, Trevor SilverstoneAbstract:Abstract Background: It has been suggested that patients with bipolar disorder may have an increased sensitivity to dopaminergic (DA) compounds. This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar Depression, Unipolar Depression and control subjects. Methods: Fourteen patients in an episode of bipolar Depression (BP), 15 in an episode of Unipolar Depression (UP) and 19 age- and gender-matched control subjects (C) participated. The growth hormone (GH) and prolactin (PRL) responses to subcutaneous administration of 0.005 or 0.008 mg/kg APO were measured over 2 h. Results: The rise in GH was greater with the higher APO dose. Both the GH rise and the PRL fall following APO were similar in BP, UP and C. Neither the GH or PRL responses in BP and UP were affected by successful treatment of the depressive episode. Conclusion: Our findings do not indicate an altered sensitivity of DA neurones in the hypothalamic–pituitary system in either bipolar or Unipolar Depression.
Jessica Hawkins - One of the best experts on this subject based on the ideXlab platform.
-
Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
CNS drugs, 2009Co-Authors: Charles Debattista, Jessica HawkinsAbstract:Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical antipsychotics may augment antidepressant effects, resulting in a greater potential for response. Atypical antipsychotics possess pharmacological actions that are associated with antidepressant properties, including serotonin 5-HT2 receptor antagonist and 5-HT1A and dopamine receptor partial agonist activity. In fact, the term ‘atypical antipsychotic’ is an unfortunate remnant of the early indication of these drugs in the treatment of schizophrenia. Soon after their introduction, the usefulness of atypical antipsychotics in bipolar disorder was firmly established and their use in the treatment of mood disorders has far outpaced their use in schizophrenia and other psychotic disorders. Aripiprazole has become the first agent to receive US FDA approval for the adjunctive treatment of Unipolar Depression. Most recently, Symbyax, a fluoxetine/olanzapine combination, received FDA approval for the acute treatment of treatment-resistant Depression. This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant Unipolar Depression is reviewed.
Charles Debattista - One of the best experts on this subject based on the ideXlab platform.
-
Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
CNS drugs, 2009Co-Authors: Charles Debattista, Jessica HawkinsAbstract:Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical antipsychotics may augment antidepressant effects, resulting in a greater potential for response. Atypical antipsychotics possess pharmacological actions that are associated with antidepressant properties, including serotonin 5-HT2 receptor antagonist and 5-HT1A and dopamine receptor partial agonist activity. In fact, the term ‘atypical antipsychotic’ is an unfortunate remnant of the early indication of these drugs in the treatment of schizophrenia. Soon after their introduction, the usefulness of atypical antipsychotics in bipolar disorder was firmly established and their use in the treatment of mood disorders has far outpaced their use in schizophrenia and other psychotic disorders. Aripiprazole has become the first agent to receive US FDA approval for the adjunctive treatment of Unipolar Depression. Most recently, Symbyax, a fluoxetine/olanzapine combination, received FDA approval for the acute treatment of treatment-resistant Depression. This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant Unipolar Depression is reviewed.
Vlado Jukić - One of the best experts on this subject based on the ideXlab platform.
-
Minor physical anomalies in women with recurrent Unipolar Depression
Psychiatry research, 2010Co-Authors: Jadranka Čulav-sumić, Vlado JukićAbstract:Abstract According to earlier observations, minor physical anomalies (MPAs) are more prevalent in psychotic disorders, especially in schizophrenia, and represent an indicator of abnormal fetal development. Limited research has been conducted on these structural abnormalities among patients with Unipolar Depression, with and without psychotic features. We hypothesized that the mean total MPA score would be greater in patients with psychotic Depression than depressive patients without psychosis and control subjects. An extended scale of MPAs was used to detect the presence or absence of 51 MPAs in women with recurrent Unipolar Depression with psychotic symptoms ( n =50), women with recurrent Unipolar Depression without psychotic symptoms ( n =50) and healthy female controls ( n =50). Women with recurrent Depression had significantly more MPAs than controls. With regard to MPAs of specific body regions, depressive patients had significantly higher rates of MPAs in the mouth area than control subjects. Higher rates of MPAs were not significantly related to psychotic features of Depression. The study results are indicative of possible early neurodevelopmental disturbance in recurrent Unipolar Depression.
